BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2004

View Archived Issues

Naturally occurring spirostenol prevents beta-amyloid-induced toxicity

Read More

Identification of active metabolites of selective COX-2 inhibitor

Read More

Behavioral improvements associated with sertraline in Alzheimer's disease

Read More

Improved glycemic control achieved with repaglinide plus pioglitazone in type 2 diabetes

Read More

Clavulanate improves the efficacy of standard therapy for H. pylori infection

Read More

Although ineffective alone, NAC in combination with deferoxamine is protective in a rat sepsis model

Read More

AnGes files IND for phase I trials of HGF

Read More

Technology transfer completed in Actelion/Merck renin alliance

Read More

Ultrafine completes scale-up of PPA-605 and PPA-904

Read More

Abbott and Corixa in agreement for Chagas' disease blood screening technology

Read More

Preliminary findings from Women's Health Initiative and memory substudy

Read More

Yakult Honsha files Japanese import application for oxaliplatin

Read More

Transgene highlights 2003 developments

Read More

Avigen continues to move forward with product development portfolio

Read More

Lilly claims new SERMs for endometriosis and uterine leiomyoma therapy

Read More

Novel NO-releasing prodrugs of COX-2 inhibitors and their use

Read More

Two novel series of chemokine CCR1 antagonists identified at Pfizer

Read More

NeuroSearch team prepares and tests new opioid receptor ligands

Read More

Guanylate cyclase as a target for the treatment of cognitive disorders

Read More

Novel iNOS inhibitors for IBD, arthritis and pain designed at AstraZeneca

Read More

Micrologix presents nucleoside-based anti-HBV agents

Read More

NIH licensing technology for improved process to produce the steroid CDB-2914

Read More

SR-4554 available for licensing from Cancer Research Technology

Read More

Canadian approval for one- and three-month Eligard products

Read More

New phase II trial for insulin sensitizer MBX-102

Read More

Phase I trials for DRF-10945 commence in Canada

Read More

German approval for Gamunex

Read More

Japanese approval for Serevent 50 Diskus

Read More

Aldara approved for actinic keratoses

Read More

Altastaph receives fast track designation

Read More

Hemispherx Biopharma cleared to commence phase II Alferon LDO study

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing